The global rheumatoid arthritis biologics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
The Biologics segment holds the highest share in the rheumatoid arthritis market in terms of revenue; its approximately 90% of the market share. Among the biologics, its anti-TNFs (~68%) have captured the major portion of the market owing to well-established efficacy, safety profile, physicians familiarities, and their long presence in the market. Among the anti-TNFs, etanercept and adalimumab were holding around 50% of the total in the major markets.
Market Drivers & Restraints
The growing demand for biologics and increasing penetration of generic drugs coupled with rising number of FDA approvals for the treatment of rheumatoid arthritis is boosting the market growth. For instance, from 2017-2018 FDA approved 2 drugs for the treatment of rheumatoid arthritis. Recently approved biologics such as Kevzara and Xeljanz are expected to boost rheumatoid arthritis therapeutics market growth owing to their strong market penetration and presence of favorable reimbursement scenario.
However, high cost of biologics and accessibility to these biologics may restrict the market growth in the upcoming years.